StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report issued on Monday. The firm issued a sell rating on the stock.
Oragenics Price Performance
OGEN stock opened at $0.32 on Monday. Oragenics has a 1 year low of $0.28 and a 1 year high of $7.74. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The company has a 50 day simple moving average of $0.45 and a 200 day simple moving average of $1.06.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.
Institutional Trading of Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.